期刊文献+

血液系统恶性肿瘤患者止凝血功能的研究 被引量:17

The Study of Heamostatic Function in Patients with Hematological Malignancy
下载PDF
导出
摘要 目的动态观察血液系统恶性肿瘤患者在疾病缓解和进展不同时期的止凝血功能的变化,以探索其止凝血机制的常规检测指标及分子标志物的改变对血液系统恶性肿瘤患者的诊断、疾病进展和预后的临床意义。方法对30例正常对照组人群及44例血液系统恶性肿瘤患者进行常规止凝血功能的检测,包括PLT、PT、aPTT、TT、Fbg及血小板活化、凝血、抗凝血和纤溶指标的分子标志物的检测,包括GMP-140、TF、TAT、TFPI、TpP、PAP、u-PA、t-PA、PAI、D-D含量和凝血因子Ⅱ、Ⅴ、Ⅶ、Ⅷ、Ⅸ、Ⅹ和Ⅺ活性及AT活性。结果 1.在血液系统恶性肿瘤组及其疾病缓解期组中存在着Fbg的升高(P<0.05),至疾病进展期中PLT、Fbg出现了下降(P<0.05)。且出现了PT、aPTT的延长(P<0.05);2.在血液系统恶性肿瘤组中,GMP-140、TF、TAT、TFPI和TpP含量的升高及AT活性的降低,在疾病进展期中变化更明显(P<0.05或P<0.01),同时有凝血因子Ⅴ、Ⅵ、Ⅷ、Ⅸ的降低(P<0.05),而在疾病缓解期时同样存在着GMP-140、TF、TpP的升高及AT活性的降低(P<0.05);3.在血液系统恶性肿瘤组中同样存在着纤溶指标PAP、u-PA、t-PA和D-D的含量的升高(P<0.05),疾病进展期升高得更明显(P<0.05或P<0.01),且同时出现了纤溶酶原抑制物PAI-1含量的升高(P<0.05)。结论血液系统恶性肿瘤患者体内同时存在着血小板、凝血、抗凝和纤溶方面的止凝血功能的异常。表现为血小板数量下降、功能活化、凝血激活、抗凝血降低和纤溶系统的活化。在血液系统恶性肿瘤中常规止凝血指标PLT、Fbg的变化与疾病的进展密切相关。而血小板活化、凝血抗凝和纤溶系统的分子标志物水平的改变对其疾病合并有止凝血功能异常的意义更明显,可作为血液系统恶性肿瘤的疾病的进展和缓解的敏感指标。 Objective To investigate the homeostatic changes of patients with hematological malignan- cy at the different stages between progress or relapse;Some routine homeostatic tests were conducted and mo- lecular markers were measured, in order to evaluate the relationships with the diagnosis, progress and progno- sis. Methods Routine haemostatic tests were conducted among 44 patients with hematological malignancy. 30 healthy volunteers were taken as controls. The test included the plasma concentration of PLT, PT, aPTT, Yl', Fbg. Some coagulable and fibrinolytic molecular markers. Such as GMP- 140, TF, TAT, TFPI, TpP, PAP, u- PA, t- PA, PAI, D-dimer were also measured. The activities of coagulation factors II , V, VI, VIU, IX, X, XI, and AT ware evaluated as well. Results ( 1 ) The plasma levels of Fbg were elevated in the group of patients with he- matological malignancy and the states in remission ( P 〈 0.05 ), However, when the disease was in progress, the concentration of PLT, Fbg decreased ( P 〈 0.05 or P 〈 0.01 ) , PT and aPTT prolonged ( P 〈 0.05 ). ( 2 ) The plasma levels of GMP-140 ,TF ,TAT and TpP were elevated in the group of patients with hematological malig- nancy and the states in remission( P 〈 0.05 ) , when the disease was in progress the changes were more signifi- cantly(P 〈0.05 or P 〈0.01 ),meanwhile decreased activity of coagulation factors V, V][, ~l, IX took place (P 〈 0.05 ). When the disease was in remission, similar changes of GMP-140, TF, TpP and AT were obtained (P 〈 0.05). However, the activities of coagulation factors V and ]X were elevated (P 〉 0.05). (3) Compared with the normal control, the patients with hematological malignancy had higher concentrations of fi- brinolytic parameters, such as PAP, u- PA, t- PA and D- dimer ( P 〈 0.05 ), while in the relapse, all these parameters raised more remarkably( P 〈 O. 05 or P 〈 O. 01 ). Furthermore, the concentration of fibrinogen inhibi- tor PAI-1 was also elevated (
出处 《血栓与止血学》 2013年第6期257-260,263,共5页 Chinese Journal of Thrombosis and Hemostasis
关键词 血液系统恶性肿瘤 疾病缓解 疾病进展 止凝血功能 常规检验 分子标志物 Hematological malignancy Relapse state Progress state Haemostatic function Routine test Molecular marker
  • 相关文献

参考文献6

  • 1TALLMAM MS. Deciphering the pathogenesis of coagulation dysfunc- tion in leukemia[ J]. Lewk Rws, 1996 ;20 : 13. 被引量:1
  • 2张之南.血液病诊断和疗效标准[M],第3版,北京:科学出版社,2008. 被引量:2
  • 3AMERI A, KUPPUSWARMY MN, BESU S, et al. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators [ J ]. Blood, 1992,79:3219. 被引量:1
  • 4BLANN AD, LIP GYH, BEEVERS BG, et al. Soluble P-selection in atherosclemsis:Acomparision with endothelial cell and platelet mark- em [ J ]. Thromb Haemost, 1997,77 : 1077 - 1079. 被引量:1
  • 5CHOROSTOWSKA- WYNIMKO J, SWIERCZ R, SKRZYPEZAK- JANKUN E. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lun vascular endothelial cells [J]. Oncol Rep,2004,12(6) :1155-1162. 被引量:1
  • 6LI P, GAO Y, JI Z, ET AL. Role of umkinase plasminoen activator and its receptor in metastasis and invasion of neuroblastoma [ J ]. J Pe- diatr Surg,2004,39(10) : 1512-1519. 被引量:1

共引文献1

同被引文献145

引证文献17

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部